{"id":"NCT05399641","sponsor":"Scynexis, Inc.","briefTitle":"Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis","officialTitle":"Oral Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis (VVC) in Subjects Who Have Failed Fluconazole Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-05-01","primaryCompletion":"2023-05-16","completion":"2023-08-02","firstPosted":"2022-06-01","resultsPosted":"2024-07-10","lastUpdate":"2024-07-10"},"enrollment":150,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Vulvovaginal Candidiasis"],"interventions":[{"type":"DRUG","name":"Ibrexafungerp","otherNames":[]}],"arms":[{"label":"Group A","type":"EXPERIMENTAL"},{"label":"Group B (3 Day dosing)","type":"EXPERIMENTAL"},{"label":"Group B (7 Day dosing)","type":"EXPERIMENTAL"}],"summary":"This study will treat subjects with complicated VVC who have failed prior fluconazole therapy with Ibrexafungerp for 1, 3 or 7 days of treatment.","primaryOutcome":{"measure":"Clinical Cure","timeFrame":"14 days post-Baseline - Test-Of-Cure (TOC)","effectByArm":[{"arm":"Group A","deltaMin":7,"sd":null},{"arm":"Group B (3 Day Dosing)","deltaMin":10,"sd":null},{"arm":"Group B (7 Day Dosing)","deltaMin":23,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":25,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["Diarrhoea","Nausea","Headache","Bacterial vaginosis","Abdominal Discomfort"]}}